Compare Regeneron Pharmaceuticals Inc (REGN) vs Raytheon Technologies Corp (RTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Raytheon Technologies Corp — how do they compare? Regeneron Pharmaceuticals Inc trades at $652.76 (market cap $70.79B), while Raytheon Technologies Corp trades at $194.53 (market cap $260.81B). The key difference: Raytheon Technologies Corp is far larger — about 3.7× Regeneron Pharmaceuticals Inc's market cap, and Raytheon Technologies Corp pays the higher dividend (1.51%). Which is the better fit depends on your goals.
| REGN | RTX | |
|---|---|---|
Market Cap | $70.79B | $260.81B |
Sector | Health | Industrials |
52-Week High | $812.27 | $212.16 |
52-Week Low | $545.46 | $149.17 |
Enterprise Value | $64.74B | $292.93B |
Dividend Yield | 0.56% | 1.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
RTX trades at $194.88, up 0.23% today, with a bullish technical signal and strong analyst support. Recent contract wins, including a $515 million Navy radar award (PRNewsWire, June 3, 2026), and expanding manufacturing capacity in Poland highlight growth momentum. The company has beaten earnings estimates in recent quarters, with Q1 2026 EPS of $1.78 surpassing the $1.51 forecast. Revenue growth accelerated to $88.6 billion in 2025, driving net income to $6.73 billion.
The outlook is positive, supported by robust defense spending and operational execution. However, a high P/E ratio of 36.34 suggests premium valuation, while rising long-term debt poses a financial risk. The stock offers a dividend yield of approximately 1.5%, with the next payment of $0.73 scheduled for September 3, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Raytheon Technologies Corp
Raytheon Technologies is a diversified aerospace and defense industrial company formed from the merger of United Technologies and Raytheon, with roughly equal exposure as a supplier to commercial aerospace manufactures and to the defense market as a prime and subprime contractor.
Read more on RTX →
